Conclusions:
The use of an everolimus-eluting stent to provide straightline inflow to the foot in patients with rest pain or ulceration and infrapopliteal disease can provide acceptable 3-year limb salvage results.
Summary: This is a prospective, single-center registry study of patients with rest pain or minor ischemic ulceration and with distal popliteal and proximal tibial artery occlusive lesions up to 10 cm in length. The treatment was revascularization using the Xience-Prime EverolimusEluting Stent of the target greater than 70% BTK denovo lesion or restenosis consisting of 20 to 100 mm in length with a vessel diameter of 2 to 3.5 mm. Ultimately, one tibial or peroneal artery must supply in-line flow to the pedal arteries related to the ischemic area of the foot. Exclusion criteria were aneurysmal disease, prior surgery, acute thrombosis, nonatherosclerotic disease, or noncompliance with antiplatelet therapy. The primary end point was primary patency defined as freedom from restenosis of target vessel (peak systolic velocity ratio $ 2.4 on duplex imaging). Secondary end points were amputation-free survival (freedom from above ankle amputation of index limb), clinical success (Rutherford-Becker classification improvement 1 or more), wound healing (complete), immediate success, target lesion revascularization (TLR) rate due to restenosis, CLI recurrence, and the cumulative rate of freedom from death and major amputation, secondary patency, and survival rates. All end points were evaluated at 1, 2, and 3 years. Some caveats of the study: femoropopliteal disease was treated at the same time with angioplasty with provisional stenting, predilation of the target lesion with a shorter and smaller balloon was allowed, the drug-coated stent must cover the entire lesion with 5-mm overlap to normal artery above and below. Follow-up was physical examination and duplex imaging with angiography preformed for duplex demonstrated restenosis or CLI symptoms. Of 423 patients with CLI treated during the 3 year recruitment (2011) (2012) (2013) (2014) , 122 patients met study criteria. The average age was 70.9, 63.9% were male, and 60.6% had ulceration. The mean lesion length was 52.7 mm (20-100 mm) with most having extensive calcification (65.2%). The BTK was occluded in 68%. Immediate success was 100%. One and two stents were used in 60.6% and 29.5% of cases respectively. Twelve cases required three stents. Five procedural complications included four hematomas treated conservatively and one pseudoaneurysm requiring surgical repair. Patients completing follow-up were 88 at 1 year, 47 at 2 years, and 34 at 3 years. Eight patients were lost to follow-up (six at 1 year, two at 3 year). Twenty-six patients died during the 3 years due to cardiac disease (n ¼ 15) and respiratory disease (n ¼ 5), and six died from cancer. Fourteen patients required secondary angiography of the target limb: 10 required target lesion revascularization and four a new intervention. The 1-and 2/3-year primary patency rates were 88.9% and 80.1%, respectively. The survival, major amputation-free survival, and freedom from target lesion revascularization rates were: 88.1%, 93%, and 91.5% at 1-year follow-up; 75.7%, 89.3%, and 85.1% at 2-year follow-up; and 70.4%, 89.3%, and 85.1% at 3-year follow-up. The secondary patency rate was 92.2% at 1 year and 85% at 2 and 3 years. The freedom from cumulative major amputation/death rate was 82.7% at 1-year follow-up and 64.3% at 2-and 3-year follow-up, respectively. Diabetes had no significant influence on the results. Primary patency influenced major amputation rate, which was a 60% amputation rate in patients with no target artery patency vs 5.4% in patients with target patency (P ¼ .022). At 1-year follow-up, 78 (88.6%) of 88 patients improved 1 or more of their Rutherford-Becker category, and 48 (80%) of 69 patients had wound healing (maintained at 85.3% in the 34 patients at the 3-year follow-up).
Comments: This single-center study provides some data to suggest that distal popliteal/proximal tibial drug-eluting stent placement can provide acceptable midterm limb salvage without excessive reintervention rates in patients with rest pain and minor ulcerations. Those with more extensive ischemia where mild/moderate improvements in perfusion might not allow salvage are not studied. It is unfortunate that no estimation of improved distal perfusion (ABI) is provided to determine the degree of improved perfusion for comparison over time. Most investigators would have provided patient outcomes (limb salvage) as primary outcome rather than the surrogate primary patent of the target lesion restenosis.
